Market Overview:
The global anti-obesity medication market size is expected to reach USD 73,470.85 million by 2032, exhibiting a CAGR of 30.8% during the forecast period.
Drug remedy assists patients in sticking to lifestyle alterations and controlling these feedbacks. Usually, monotherapy causes a loss of 3% to 8% of aggregate body weight from onset, and merger therapy can cause even a profound loss. Additionally, some anti-obesity drugs can offer individualistic health advantages such as reduction in blood pressure, detrimental lipid levels, waist perimeter, insulin aversion, non-alcoholic fatty liver illnesses, probability of prominent cardiovascular events, and advancement of diabetic kidney illnesses.
The growing pervasiveness of obesity and overweight persons globally originating from desk-bound lifestyles and substandard dietary patterns is expected to push growth in the anti-obesity medication market. Prominent industry players are diligently occupied in commodity advancement and looking for market consent to entertain the escalating global population struggling with obesity. Also, the growing pervasiveness of obesity and type II diabetes has prompted several studies by market analysis and vendors to concentrate on advancing drugs capable of inscribing both conditions at the same time.
Download Free Sample PDF Copy of the Report:
Competitor Analysis:
Some of the major global players include:
- Boehringer Ingelheim International GmbH
- Currax Pharmaceuticals
- Gelesis
- GlaxoSmithKline plc
- Kintai Therapeutics
- Novartis AG
- Novo Nordisk A/S
- Rhythm Pharmaceuticals, Inc.
- VIVUS LLC
Segmental Outlook:
Anti-Obesity Medication Market, Mechanism of Action Outlook (Revenue – USD Million, 2019-2032)
- Centrally Acting Drugs
- Peripherally Acting Drugs
Anti-Obesity Medication Market, Product Outlook (Revenue – USD Million, 2019-2032)
- Off Label
- Semaglutide (Wegovy)
- Topiramate (Xenical Alli)
- Dulaglutide (Trulicity)
- Liraglutide (Semaglutide (Wegovy))
- Others
- Approved
- Liraglutide (Orlistat)
- Bupropion-naltrexone (Contrave)
- Orlistat
- Alli
- Xenical
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy)
Anti-Obesity Medication Market, Distribution Channel Outlook (Revenue – USD Million, 2019-2032)
- Hospital Pharmacies
- Retail Pharmacies
- Others
The research report categorizes the market into various segments and sub-segments. The primary segments covered in the study include type, application, end use and region. The splitting of the market into various groups enables businesses to understand market preferences and trends better. Also, stakeholders can develop products/services that align with the diverse needs of consumers in the industry. Besides, the research study includes a thorough examination of all the major sub-segments in the market.
Recent Developments in the Obesity Medication Market:
- Roche Acquires Carmot Therapeutics (January 2024)
Carmot Therapeutics announced its acquisition by Roche, enabling Roche to access Carmot’s clinical-stage obesity drugs portfolio. This includes CT-388, a flagship drug aimed at treating obesity and related conditions, bolstering Roche’s position in the growing obesity therapeutics sector. - Novo Nordisk Expands Production Facilities in France (November 2023)
Novo Nordisk committed over USD 2.32 billion to expand its manufacturing capabilities in Chartres, France. This investment targets increased production for addressing chronic diseases, including anti-obesity medications, reflecting confidence in the market’s expansion and demand.
Anti-obesity medications are pharmaceutical substances crafted to aid individuals in controlling and reducing their surplus body weight, particularly when lifestyle modifications like dietary adjustments and physical activity alone prove insufficient for attaining and sustaining a healthy weight. These medications can operate through diverse mechanisms, such as modifying metabolism, inhibiting fat absorption, and suppressing appetite. Healthcare providers typically prescribe them to patients meeting specific criteria, such as those with elevated body mass index (BMI) or obesity-related health issues like type 2 diabetes.